A deep dive into the bidirectional relationship between chronic low-grade inflammation, weight gain, insulin resistance, and metabolic disease, with specific clinical data, named trials, and actionable guidance.
GLP-1 receptor agonists drive significant weight loss, but up to 40% of that lost weight can be lean mass. This evidence-based guide covers protein targets, resistance training protocols, and clinical strategies to protect muscle while on semaglutide or tirzepatide.
A complete guide to PCOS diagnosis: which blood tests, imaging, and clinical criteria doctors use, what normal and abnormal results mean, and how to prepare for each step.
Processed foods disrupt gut microbiome diversity, trigger chronic low-grade inflammation, and hijack appetite-regulating hormones. Learn the specific mechanisms, the clinical evidence, and what dietary changes actually move the needle.
PCOS runs in families, but the inheritance pattern is complex. Learn what genetic research, twin studies, and candidate gene data tell us about your family risk and what to do about it.
A complete guide to Cigna coverage for Trulicity (dulaglutide), including formulary tier, prior authorization criteria, step therapy requirements, denial appeals, and manufacturer savings options.
A guide to dulaglutide (Trulicity) overdose: symptoms, mechanisms, treatment protocols, and when to seek emergency care.
A comparison of compounded dulaglutide versus branded Trulicity, covering FDA approval status, clinical trial evidence from REWIND, safety differences, cost, and who qualifies for each option.
A clinical deep-dive into how dulaglutide (Trulicity) affects liver enzymes, hepatic fat, and NAFLD/MASH. Covers REWIND trial data, ALT/AST findings, and prescribing guidance for patients with liver disease.
Stopping dulaglutide (Trulicity) can trigger glycemic rebound, weight regain, and loss of cardiovascular protection. Learn what the clinical evidence supports, what remains unverified, and how to plan a discontinuation with your care team.
A careful look at how dulaglutide (Trulicity) plausibly affects sleep, including GLP-1 receptor biology, nausea-related sleep disruption during titration, and the indirect route from weight loss to obstructive sleep apnea improvement. Notes where dedicated polysomnography evidence does not exist.
A guide to dutasteride (Avodart) safety in adults aged 30, 49, covering sexual side effects, cardiovascular signals, cancer risk, drug interactions, and how to weigh risks against benefits for BPH and hair loss.
Find out whether Cigna covers Avodart (dutasteride) for BPH and hair loss, what prior-authorization criteria apply, how step therapy works, and how to appeal a denial.
A clinical guide to dutasteride (Avodart) monitoring in adults 65 and older, covering falls risk, renal considerations, drug interactions, PSA interpretation, and deprescribing thresholds.
A guide to dutasteride (Avodart) monitoring protocols for men and women aged 50 to 64, covering PSA interpretation, cardiovascular checks, hormone interactions, and safety labs at each follow-up visit.
A clinician-level review of dutasteride (Avodart) dosing in renal impairment, covering pharmacokinetics, mechanism of action, trial data, and practical prescribing guidance.
Everything clinicians and patients need to know about switching between dutasteride, finasteride, and other 5-alpha-reductase inhibitors, with trial evidence, dosing protocols, and pharmacokinetic rationale.
A guide to dutasteride (Avodart) monitoring for men aged 18 to 29, covering labs, fertility, sexual side effects, PSA interpretation, and when to stop treatment.
A guide to dutasteride safety in young adults ages 18, 29, covering sexual side effects, fertility, mental health signals, contraindications, and monitoring protocols with primary-source citations.
Does dutasteride (Avodart) change appetite or food cravings? A deep dive into the pharmacology, clinical trial data, and patient reports around dutasteride and appetite.
A review of dutasteride (Avodart) and the prostate cancer risk signal, covering the REDUCE trial, the FDA's 2011 safety communication, the PSA masking effect, and what this means for men using dutasteride for BPH or for off-label hair loss.
A deep dive into dutasteride (Avodart) and long-term cardiovascular risk, covering the REDUCE trial, PCPT-era data, MACE signals, lipid effects, and current prescribing guidance for men on 5-alpha-reductase inhibitor therapy.
A comparison of compounded dutasteride versus branded Avodart covering bioavailability, cost, regulatory status, and clinical evidence for BPH and hair loss.
A deep dive into dutasteride (Avodart) and its effects on mood, depression, anxiety, libido, and cognitive function, with primary-literature citations and clinical guidance.
A deep dive into dutasteride microdosing protocols for AGA and BPH, covering every published dose-finding trial, pharmacokinetics, sexual side-effect profiles, and how to discuss sub-standard doses with your prescriber.
A clinician-level review of dutasteride (Avodart) and muscle preservation strategies, covering DHT suppression, resistance training protocols, protein targets, and monitoring guidance backed by primary-source evidence.
What happens when you stop dutasteride during illness, when it's safe to restart, and exactly how to resume therapy after acute illness. guidance with primary-literature citations.
Board-reviewed guide on the dutasteride (Avodart) pre-surgery hold window: when to stop, why it matters for PSA, bleeding, and anesthesia, and how to safely restart.
An evidence-based breakdown of what happens when you stop dutasteride (Avodart): DHT rebound, hair loss reversal, BPH symptom return, and how to taper safely.
A guide to dutasteride (Avodart) seasonal use considerations, covering how shedding cycles, temperature, storage, and monitoring schedules interact with 5-alpha reductase inhibitor therapy.
An evidence-based look at how dutasteride (Avodart) affects sexual function, including libido, erectile function, and ejaculation, with data from major trials and practical clinical context.
A clinician-level review of how dutasteride (Avodart) affects sleep architecture, including neurosteroid suppression, REM disruption, and clinical management strategies backed by primary literature.
A detailed clinical guide to monitoring enclomiphene citrate therapy in adolescent males aged 12-17 with secondary hypogonadism, covering lab schedules, growth surveillance, mental health tracking, and safety thresholds.
A guide to enclomiphene citrate dosing in men aged 65 and older, covering starting doses, titration, renal and hepatic adjustments, fall risk, drug interactions, and monitoring protocols for secondary hypogonadism.
Does enclomiphene citrate change appetite or cravings? A clinician-level review of the mechanisms, clinical trial data, and practical guidance for men on enclomiphene therapy.
A physician-level review of the cancer risk signals associated with enclomiphene citrate, covering estrogen receptor pharmacology, published trial safety data, and how clinicians should counsel patients on off-label use for secondary hypogonadism.
A deep dive into how enclomiphene citrate affects testosterone, metabolic rate, body composition, and energy expenditure, with primary-literature citations and clinical dosing guidance.
A physician-level guide to safely restarting enclomiphene citrate after acute illness, covering when to pause, how to re-titrate, and what lab values guide the decision.
When and how long to hold enclomiphene citrate before surgery, with evidence-based dosing, pharmacokinetics, and perioperative management protocols for clinicians and patients.
A deep dive into how enclomiphene citrate affects sleep architecture, REM sleep, slow-wave sleep, and testosterone-driven circadian signaling in men with secondary hypogonadism.
A safety guide for epitalon tetrapeptide use in adults aged 50 to 64, covering current evidence, contraindications, drug interactions, and monitoring recommendations.
A clinician-level guide to switching protocols for epitalon tetrapeptide, covering mechanism, class comparisons, dosing cycles, and evidence-based transition strategies with primary-source citations.
A complete clinical monitoring guide for adults aged 18-29 using epitalon tetrapeptide, covering baseline labs, cycle tracking, fertility considerations, and safety checkpoints backed by primary research.
A clinical review of epitalon tetrapeptide safety in adults aged 18, 29, covering telomere biology, known risks, dosing considerations, fertility implications, and what current evidence does and does not support.
A physician-level review of epitalon tetrapeptide's long-term cardiovascular effects, covering telomerase biology, oxidative stress, lipid profiles, and what Russian cohort data and preclinical trials reveal about heart health outcomes.
A clinician-level review of how epitalon tetrapeptide affects hair follicle cycling, collagen synthesis, and skin aging, with primary-literature citations and dosing context.
A clinician-level review of epitalon tetrapeptide's effects on mood, anxiety, sleep architecture, and neurochemistry, with primary-literature citations and dosing context.
A deep dive into how epitalon tetrapeptide may affect sexual function, covering telomerase biology, gonadotropin signaling, circadian rhythm repair, and what real clinical data says about libido, erectile function, and hormonal balance.
A deep dive into how the tetrapeptide Epitalon affects sleep architecture, melatonin secretion, circadian rhythm regulation, and sleep quality in aging adults, with primary-literature citations throughout.
A guide to using epitalon tetrapeptide during travel and timezone shifts, covering dosing windows, circadian biology, and jet-lag mitigation protocols with primary-literature citations.
A clinician-level review of how oral estradiol affects hair growth, hair loss, skin thickness, collagen, sebum, and wound healing, with primary-literature citations and practical dosing context.
A clinician-level review of eszopiclone (Lunesta) and its reported effects on hair and skin, including dermatologic adverse events from FDA labeling, published trials, and real-world pharmacovigilance data.
A clinical deep-dive into AOD-9604 (HGH fragment 176-191) dosing for Hispanic and Latino patients, covering pharmacogenomics, insulin resistance phenotypes, CYP variant data, and evidence-based dose adjustment strategies.
A deep clinical review of BPC-157 efficacy differences in East Asian patients, covering CYP2C19/CYP2D6 polymorphisms, BMI-adjusted dosing, and the current state of ethnicity-stratified trial data.
A guide to tadalafil dosing in South Asian patients, covering CYP3A4 and CYP2C9 variants, cardiovascular risk at lower BMI, drug interactions with metformin and statins, and evidence-based dose adjustment protocols.
A clinical deep-dive into dutasteride (Avodart) efficacy differences in Hispanic and Latino patients, covering pharmacogenomics, CYP enzyme variants, ethnicity-stratified trial data, and evidence-based dosing considerations.
A clinical review of whether Epitalon (epitalon tetrapeptide) works differently in East Asian patients, covering pharmacogenomic variation, dosing considerations, and what the current evidence actually shows.
A clinician-focused guide to finasteride dosing, pharmacogenomics, and efficacy evidence in Black and African ancestry patients, including SRD5A2 variant data, ethnicity-stratified trial subgroups, and practical prescribing guidance.
A guide to finasteride pharmacogenomics, dosing considerations, and safety differences in Hispanic and Latino patients, with ethnicity-stratified data, PharmGKB references, and practical prescribing guidance.
A clinical review of how finasteride performs in South Asian men with androgenetic alopecia, covering pharmacogenomics, SRD5A2 polymorphisms, ethnicity-stratified trial data, and dosing considerations for this population.